Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)FDA Approves First Bispecific Antibody for Multiple Myeloma

The MajesTEC-1 trial, a phase 1/2 open-label research that revealed effectiveness data from 110 patients with relapsed or refractory multiple myeloma, provided evidence from strong response rates that served as the foundation for the approval. The accelerated approval of a bispecific antibody for the incurable blood malignancy is a first of its kind in the US. Proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody must have been used in prior therapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form